Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01034358 · ClinicalTrials.gov registry record · Phase 4

Immune Response to the Human Papillomavirus Vaccine in Young Women With Inflammatory Bowel Disease

A Phase 4 study of Inflammatory Bowel Disease and Uterine Cervical Dysplasia, sponsored by Mayo Clinic.

Completed
Registry status
Phase 4
Development phase
15
Enrollment target
1
Study location

NCT01034358 is a Phase 4 study of Inflammatory Bowel Disease and Uterine Cervical Dysplasia that has completed, run by Mayo Clinic. The registered enrollment target is 15 participants, below the 403-participant average among 28 other Inflammatory Bowel Disease trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01034358, a Phase 4 study of Inflammatory Bowel Disease and Uterine Cervical Dysplasia, has completed, sponsored by Mayo Clinic.

COMPLETED
Registry status
Phase 4
Development phase
15 participants
Enrollment target
1
Study location

Study Summary

The Gardasil vaccine, a vaccine targeted towards the human papillomavirus (HPV), has been shown to prevent the transmission of several strains of HPV in young women. Women with inflammatory bowel disease (IBD) may not respond as well to this vaccine, either due to having IBD or due to immunosuppressants used to control IBD. This study will test how well women with IBD respond to the Gardasil vaccine.

Interventions

  • BIOLOGICAL Human Papillomavirus Vaccine

Study Locations (1)

Minnesota

  • Mayo Clinic - Rochester

Trial Details

FieldValue
Enrollment Target 15 participants
Start Date 2010-02
Est. Completion 2011-06
Phase Phase 4

Sponsor

Mayo Clinic

2,844 total trials

What the Registry Record Tells You About NCT01034358

The ClinicalTrials.gov registry entry for NCT01034358 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 403-participant average among 28 other Inflammatory Bowel Disease trials with a reported enrollment target (96% lower). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Inflammatory Bowel Disease appearing as the primary indexed condition, and to 1 intervention - of which Human Papillomavirus Vaccine is the first listed.

NCT01034358 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.

Frequently Asked Questions

What is clinical trial NCT01034358 about?

NCT01034358 is a clinical study titled "Immune Response to the Human Papillomavirus Vaccine in Young Women With Inflammatory Bowel Disease". The Gardasil vaccine, a vaccine targeted towards the human papillomavirus (HPV), has been shown to prevent the transmission of several strains of HPV in young women. Women with inflammatory bowel disease (IBD) may not respond as well to this vaccine, either due to having IBD or due to immunosuppress...

What is the current status of trial NCT01034358?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 15 participants. The study started on 2010-02. Estimated completion is 2011-06.

What conditions does trial NCT01034358 study?

This clinical trial studies the following conditions: Inflammatory Bowel Disease, Uterine Cervical Dysplasia.

What interventions are being tested in trial NCT01034358?

The interventions under investigation include: Human Papillomavirus Vaccine (BIOLOGICAL).

Who is sponsoring clinical trial NCT01034358?

This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01034358 being conducted?

This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Inflammatory Bowel Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.